IntuitionLabs
21 CFR Part 11 compliant pharmaceutical software development

21 CFR Part 11 Compliant Software Development

Purpose-built pharmaceutical software with electronic records, electronic signatures, audit trails, and data integrity controls that satisfy FDA requirements from day one.

Schedule Free Consultation

Building Software That Meets FDA Electronic Records Requirements

21 CFR Part 11, published March 20, 1997, establishes criteria for electronic records and signatures to be equivalent to paper records and handwritten signatures in FDA-regulated industries. Any system that creates, modifies, maintains, archives, retrieves, or transmits records required by FDA predicate rules must comply. Non-compliance risks warning letters, 483 observations, consent decrees, and manufacturing shutdowns — all far more costly than building compliance in from the start.

Pharmaceutical regulatory compliance documentation and FDA requirements

Section 11.10: Controls for Closed Systems

Section 11.10 specifies eleven controls every closed system must implement: system validation, generating accurate copies for FDA inspection, protecting records throughout mandatory retention periods, limiting access to authorized individuals, maintaining immutable computer-generated audit trails, enforcing permitted workflow sequencing, authority checks, device checks, personnel training records, written policies, and documentation controls. Every system we build satisfies all eleven requirements by design, not as an afterthought.

Pharmaceutical software access controls and audit trail architecture

Electronic Signatures Under Subpart C

Part 11 Subpart C requires each electronic signature to be unique to one individual and never reused or reassigned. Non-biometric signatures must use at least two identification components — typically a user ID and password — with both required at initial signing in a session. Every signed record must include the signer's printed name, the date and time of signing, and the meaning of the signature. Signatures are cryptographically bound to their records via content hashing, making tampering immediately detectable.

Electronic signature workflow and identity management for pharmaceutical systems

Computer Software Assurance: Risk-Based Validation

The FDA's Computer Software Assurance guidance, finalized September 2024, shifts from documentation-heavy CSV toward risk-based assurance aligned with ISPE GAMP 5 Second Edition and ICH Q9(R1). GxP-critical functions receive rigorous scripted testing; lower-risk features are covered by unscripted exploratory testing. This risk stratification reduces validation overhead substantially while maintaining the highest level of assurance where patient safety and data integrity are actually at stake.

Risk-based computer software assurance methodology for GxP pharmaceutical validation

Predicate Rules and Part 11: [Which Systems Need Compliance]

Part 11 applies specifically to records required under FDA predicate rules — the underlying regulations governing pharmaceutical manufacturing, clinical research, and product quality. The FDA's 2003 Scope and Application guidance focused enforcement on these predicate rule requirements, making it essential to understand which regulations govern your operations.

Drug Manufacturing (cGMP)
21 CFR Part 211 requires batch production records, laboratory records, distribution records, complaint files, and records retention. Any electronic system managing these records must comply with Part 11. This covers the majority of pharmaceutical manufacturing software including MES, LIMS, and QMS platforms.
Medical Devices (QSR)
21 CFR Part 820 requires design history files, device master records, device history records, and quality system records. Software used for device design, manufacturing, or quality management must be Part 11 compliant and may also fall under IEC 62304 and ISO 13485.
Good Laboratory Practice (GLP)
21 CFR Part 58 requires raw data preservation, protocol documentation, and final study reports for nonclinical studies. LIMS, electronic lab notebooks, and chromatography data systems used in GLP studies must implement Part 11 controls. Data integrity expectations are especially rigorous in this context.
Clinical Investigations
21 CFR Part 312 (IND) and 21 CFR Part 314 (NDA) require extensive record keeping across the clinical development lifecycle. EDC systems, CTMS, safety databases, and regulatory submission systems all fall under Part 11 when they maintain records required by these predicate rules.

FDA Warning Letters and 483 Observations: Common Part 11 Findings

Analysis of FDA warning letters and 483 inspection observations reveals consistent patterns in Part 11 and data integrity citations. Understanding these failure modes allows us to design software that proactively addresses the most common inspection findings before they arise.

!

Inadequate or Absent Audit Trails

The most common citation involves systems that lack audit trail functionality, have incomplete trails, or allow users to disable or modify audit records. Inspectors frequently find systems where administrators can alter audit data, or where original values before changes are not captured. Our systems generate immutable audit trails that cannot be disabled, modified, or deleted by any user role, including system administrators.

!

Shared User Accounts

Inspectors frequently cite shared login credentials and generic user accounts such as "Lab1" or "QC_User" — patterns that make it impossible to attribute actions to specific individuals and fundamentally undermine data integrity. Our identity management enforces unique individual accounts, prohibits credential sharing through technical controls, and provides automated periodic access review workflows.

!

Insufficient Backup and Recovery

Citations in this category involve organizations that cannot demonstrate they can recover electronic records after system failure, or that have not tested backup restoration procedures. We implement automated backup procedures with geographic redundancy, regular restoration testing, and documented evidence of each restoration test that quality personnel can present during inspection.

!

Data Integrity Failures

The FDA has intensified focus on data integrity since the mid-2010s. Common findings include the ability to delete or overwrite original analytical data, absence of controls preventing backdating, and re-processing of data without retaining original results. The FDA Data Integrity Q&A guidance clarifies expectations in detail.

!

Incomplete or Missing Validation

Systems deployed without adequate validation documentation — missing validation plans, test protocols that omit critical functionality, absent traceability matrices, or failure to revalidate after changes — are regularly cited. We deliver complete validation packages with every deployment and maintain traceability matrices linking user requirements through functional specifications to executed test cases.

!

Inadequate Change Control

Uncontrolled changes to validated systems invalidate the validated state and create significant regulatory exposure. Inspectors look for evidence that system changes follow a documented change control process including impact assessment, risk evaluation, required testing, and quality unit approval. We build change control workflows directly into our systems and provide SOP templates aligned with industry expectations.

ALCOA+: The Global Data Integrity Standard

ALCOA+ — Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available — is the data integrity framework endorsed by the FDA, WHO TRS 996, MHRA, and PIC/S PI 041-1. Software implements ALCOA+ through mandatory user attribution on every transaction, NTP-synchronized server-side timestamps that prevent backdating, append-only storage for original records, multi-level input validation, referential integrity constraints, and redundant qualified storage.

ALCOA+ data integrity principles implemented in pharmaceutical software systems

Cloud Qualification for GxP Systems

Cloud-hosted GxP systems use a shared responsibility model: the provider secures infrastructure; the regulated organization ensures Part 11 application compliance. Our qualification protocol evaluates providers against ISO 27001, SOC 2 Type II, and CSA STAR, maps each Part 11 control to the responsible party, and establishes SLAs with GxP-specific uptime and incident response requirements. Open system encryption requirements under Section 11.30 are satisfied through TLS 1.3 in transit and AES-256 at rest with customer-managed keys where required.

Cloud infrastructure qualification for GxP pharmaceutical systems

Data Migration: Maintaining Compliance During Transitions

Data migration between pharmaceutical systems is a regulated activity requiring a validated protocol. Our methodology includes a complete data inventory and element-level mapping, followed by automated verification: record count reconciliation, field-level checksum comparison, referential integrity confirmation, audit trail continuity validation, and electronic signature linkage verification. Legacy data that cannot migrate is preserved in a qualified archive satisfying Section 11.10(c) retrieval requirements for the full predicate rule retention period.

Validated data migration process for Part 11 compliant pharmaceutical systems

Periodic Review and System Decommissioning

Validation is not a one-time event. ISPE GAMP 5 recommends annual periodic reviews for GxP-critical systems; EU Annex 11 Section 11 requires them explicitly. Our systems include automated compliance dashboards monitoring audit trail integrity, user access appropriateness, backup health, and certificate validity. System decommissioning follows a formal protocol including data archival, verified accessibility for the full retention period under 21 CFR 211.180, quality unit sign-off, and complete access revocation.

Periodic review compliance dashboard and system retirement protocol for GxP systems

Types of Systems We Build With Part 11 Compliance

Purpose-built pharmaceutical software across the regulated lifecycle, each designed with full Part 11 controls from the ground up — audit trails, electronic signatures, and access controls as core infrastructure.

Laboratory Information Management (LIMS)

Sample tracking, test execution, result capture, out-of-specification investigations, instrument integration, and certificate of analysis generation with complete audit trails, electronic approvals, and calibration status enforcement.

Learn more

Electronic Batch Records (EBR)

Digital batch production records replacing paper-based manufacturing documentation. Real-time data capture, in-process checks, deviation management, and electronic release with enforced workflow sequencing under 21 CFR Part 211.

Learn more

Quality Management Systems (QMS)

Deviation tracking, CAPA management, change control, document management, and supplier qualification with role-based electronic approvals, complete traceability, and automated escalation workflows.

Learn more

Clinical Data Management Systems

Electronic data capture (EDC), clinical trial management, safety databases (pharmacovigilance), and regulatory submission systems with Part 11 electronic signatures and data integrity controls across the clinical lifecycle.

Learn more

Document Management Systems (DMS)

Controlled document creation, review and approval workflows, version control, periodic review scheduling, and distribution management with electronic signatures and full document lifecycle audit trails.

Learn more

Training & Competency Management

Training curriculum design, assignment tracking, competency assessment, training record management, and compliance reporting to satisfy 11.10(i) personnel qualification requirements and GxP training obligations.

Learn more

International Regulatory Alignment: [Beyond FDA Part 11]

Pharmaceutical companies operating globally must satisfy not only FDA Part 11 but equivalent electronic records regulations from international authorities. We design systems to satisfy the most stringent requirements across all applicable frameworks simultaneously — avoiding the need for region-specific variants.

EU GMP Annex 11
EU GMP Annex 11 (updated 2011) addresses computerised systems in manufacturing, quality control, and storage of medicinal products. It is more prescriptive than Part 11 in several areas, including requirements for formal risk management, data migration validation, business continuity planning, and third-party system provider quality system demonstration.
PIC/S Guidance
The Pharmaceutical Inspection Co-operation Scheme issues guidance adopted by over 50 member regulatory authorities worldwide. PIC/S PI 011-3 covers computerised systems in GMP environments, while PIC/S PI 041-1 specifically addresses data integrity — together creating a de facto global standard influencing inspection practices across member states.
WHO Technical Reports
WHO TRS 996, Annex 5 on data integrity and WHO TRS 1033, Annex 4 on good data and record management practices set standards adopted by regulatory authorities in emerging markets and referenced by WHO prequalification assessments.
MHRA and TGA Data Integrity
The UK MHRA Data Integrity guidance (updated March 2018) and Australian TGA data integrity guidance provide influential perspectives on electronic records expectations. The MHRA guidance is widely referenced across the industry for its practical approach to data governance.
ICH Quality Guidelines
ICH Q7 for API GMP, ICH Q9(R1) for quality risk management, and ICH Q10 for pharmaceutical quality system form the quality management framework within which all electronic records systems operate globally.
ISPE GAMP and Baseline Guides
ISPE GAMP 5 Second Edition is the industry-standard framework for GxP computerized system validation, providing risk-based categorization, specification, verification, and lifecycle management. The GAMP Records and Data Integrity Guide specifically addresses electronic records data integrity requirements.

Your Part 11 Compliance Lead

Adrien Laurent, Founder & Principal Engineer

  • 25+ years of enterprise software development in regulated industries
  • Deep expertise in 21 CFR Part 11, EU Annex 11, and GAMP 5 validation
  • Specializes in audit trail architecture, electronic signatures, and data integrity controls
  • Builds GxP-compliant software systems for pharmaceutical and biotech companies daily
Schedule a consultation
Adrien Laurent, Founder & Principal Engineer at IntuitionLabs

Why Build Part 11 Systems With IntuitionLabs?

Deep regulatory expertise combined with modern software engineering — Part 11 requirements are baked into our architecture from the first line of code, not bolted on as an afterthought. What sets us apart is that we speak both languages: the language of FDA inspectors and the language of software engineers.

Compliance by Design, Not Retrofit

Audit trails, access controls, and electronic signatures are core infrastructure in every system we build — not add-on modules. Inspection-ready documentation ships with every deployment: validation plans, test protocols, traceability matrices, and summary reports that satisfy FDA, EMA, and international authorities.

Schedule a consultation

CSA-Aligned Validation

We apply the FDA's Computer Software Assurance methodology, focusing rigorous scripted testing on GxP-critical functions while using efficient unscripted testing for lower-risk features. This reduces validation timelines without compromising quality or regulatory compliance — and results in better testing, not just less of it.

Custom development services

International Regulatory Coverage

Our systems comply with EU Annex 11, PIC/S PI 011-3, MHRA Data Integrity guidance, and WHO TRS 996 — not just FDA Part 11. One system, one validation package, global compliance.

Learn more

Veeva Ecosystem Integration

As a Veeva X-Pages partner, we build Part 11 compliant systems that integrate seamlessly with Veeva Vault, CRM, and other Veeva solutions — maintaining full compliance across the integration layer, not just within the application boundary.

Veeva services

AI-Accelerated Development

We leverage AI-assisted development to deliver compliant systems faster and at lower cost without compromising regulatory rigor. Our modern engineering practices reduce time to first deployment while maintaining the validation documentation quality that survives FDA inspection.

AI for pharma

Domain Experts, Not Generalists

25 years of pharmaceutical technology experience including GxP system validation, Part 11 compliance, and regulated software development across the full drug lifecycle. Our team has seen what FDA inspectors look for — and builds to that standard from day one.

Meet the team

Our Technical Architecture for [Part 11 Systems]

Achieving Part 11 compliance requires deliberate architectural decisions that cannot be retrofitted after deployment. The following patterns form the foundation of every system we build — these are the specific technical controls that satisfy FDA inspection requirements.

Immutable Audit Trail Architecture
Append-only database tables with cryptographic hash chains prevent any modification of audit records, even by database administrators. Every change to regulated data generates an audit entry before the change is committed, capturing who, what, when, prior value, and new value.
Cryptographic Signature Binding
Electronic signatures are bound to signed records through SHA-256 content hashing. Any modification to the signed content invalidates the hash, making tampering immediately detectable during routine integrity checks or FDA inspection.
Server-Side Timestamp Authority
All timestamps originate from NTP-synchronized server clocks, never from client devices. Timestamp integrity is verified through periodic NTP drift monitoring with automated alerting if synchronization deviates beyond configurable thresholds.
Defense-in-Depth Access Control
Multi-layer access enforcement: network-level segmentation, application-level RBAC with least privilege, API-level authorization, database-level row security, and field-level encryption for sensitive data. No single compromised layer exposes regulated data.
Validated Backup and Recovery
Automated backup procedures with geographic redundancy, point-in-time recovery capability, and quarterly restoration testing with documented evidence. Recovery time and recovery point objectives are defined per system criticality and aligned with predicate rule retention requirements.
Continuous Compliance Monitoring
Automated dashboards that monitor audit trail integrity, access control compliance, backup health, certificate validity, and system performance against validated parameters. Deviations trigger real-time notifications to quality personnel before they become inspection findings.

21 CFR Part 11 Software Development: [Frequently Asked Questions]

21 CFR Part 11 is the FDA regulation that establishes criteria for accepting electronic records and electronic signatures as equivalent to paper records and handwritten signatures. Published in 1997 and clarified by the 2003 FDA Part 11 Scope and Application guidance, it applies to any computerized system that creates, modifies, maintains, archives, retrieves, or transmits records required by FDA predicate rules. Non-compliance can result in FDA warning letters, 483 observations, consent decree requirements, and in severe cases, product seizure or injunction. Every pharmaceutical software system that handles regulated data must be designed with Part 11 controls from the ground up, not retrofitted after development.
The 2003 FDA Part 11 Scope and Application guidance adopted a risk-based approach, narrowing the scope of Part 11 enforcement. The FDA stated it would exercise enforcement discretion for certain requirements while focusing on predicate rule compliance. Systems that maintain records required by predicate rules and use electronic signatures in lieu of handwritten signatures remain fully subject to Part 11. Systems that merely automate internal processes without regulatory record obligations may have reduced compliance requirements. However, the FDA emphasized that data integrity expectations from predicate rules still apply regardless of Part 11 enforcement discretion.
CSV is the traditional approach defined in the 2002 General Principles of Software Validation guidance, emphasizing exhaustive scripted testing and comprehensive documentation. CSA, introduced in the 2022 draft and finalized in September 2024, shifts toward risk-based testing with critical thinking. CSA encourages unscripted exploratory testing for lower-risk functions and reserves rigorous scripted testing for high-risk GxP-critical features. The practical difference is a significant reduction in documentation overhead for non-critical functions while maintaining the same level of assurance for patient safety and data integrity. We design our validation approach using CSA principles where appropriate, focusing testing effort where it matters most.
Our audit trail implementation follows 21 CFR 11.10(e) requirements for computer-generated, time-stamped audit trails that independently record the date and time of operator entries and actions. Every audit trail entry captures the who (authenticated user identity), what (the field or record changed), when (server-side UTC timestamp from a qualified time source), the previous value, and the new value. Audit trails are stored in append-only database structures that prevent modification or deletion, even by system administrators. We implement cryptographic hashing to detect any tampering, and audit trail review interfaces allow quality personnel to filter, search, and export records for regulatory review.
Part 11 defines two categories of electronic signatures under Subpart C. Biometrics-based signatures use a unique biological characteristic such as a fingerprint or retinal scan. Non-biometric signatures use at least two distinct identification components, typically a user ID and password. For continuous signing sessions, the initial signing requires both components, while subsequent signings may use one component if the session has not been interrupted. Each electronic signature must be linked to its respective electronic record, must include the printed name of the signer, the date and time of signing, and the meaning of the signature such as review, approval, or responsibility. We implement both types and ensure signatures cannot be reused, reassigned, or repudiated.
Cloud-hosted GxP systems require a shared responsibility model where the cloud service provider handles infrastructure controls and we ensure application-level Part 11 compliance. We qualify cloud providers by verifying ISO 27001 certification, SOC 2 Type II attestation, and CSA STAR registration. A cloud qualification protocol documents the provider assessment, data residency requirements, encryption at rest and in transit, backup and disaster recovery testing, and the provider change management processes. The application layer implements all Part 11 controls including access controls, audit trails, and electronic signatures independent of the infrastructure. We also establish Service Level Agreements that address GxP-specific uptime, data integrity, and incident response requirements.
ALCOA+ is the framework for data integrity established by the WHO Technical Report Series No. 996 and endorsed by the FDA Data Integrity guidance. It stands for Attributable, Legible, Contemporaneous, Original, and Accurate, with the plus adding Complete, Consistent, Enduring, and Available. In software, we implement this through mandatory user attribution on every data entry, human-readable data formats, server-side timestamps that cannot be manipulated, preservation of original data with changes tracked through audit trails, input validation and range checks, referential integrity constraints, cross-field validation, qualified database storage, and role-based access controls.
Data migration for Part 11 systems follows a validated protocol that treats the migration as a regulated process. We begin with a complete data inventory and mapping between source and target systems, including metadata and audit trail data. Migration validation includes automated record count reconciliation, field-level data comparison using checksums, verification of data relationships and referential integrity, audit trail continuity verification, and electronic signature linkage confirmation. We execute the migration protocol with pre-approved acceptance criteria, document any discrepancies with root cause analysis, and generate a formal migration validation report. Legacy data that cannot be migrated retains accessibility through archived system access or certified data extracts per 11.10(c) requirements for record protection and retrieval.
FDA investigators follow established inspection procedures that focus on data integrity and system controls. They typically review system access controls and user account management, examine audit trail configurations and sample audit trail entries for completeness, verify electronic signature implementations and their linkage to records, assess backup and disaster recovery procedures and test restoration, review validation documentation including requirements, test protocols, and deviation reports, and evaluate change control procedures for system modifications. Common findings include inadequate audit trail configurations, shared user accounts, lack of periodic access reviews, insufficient backup testing, and incomplete validation documentation. We design our systems to address every item on the typical FDA inspection checklist so your team can confidently demonstrate compliance during any inspection.
Maintaining the validated state requires ongoing periodic review, which we build into every system as automated compliance monitoring. Periodic reviews assess continued user access appropriateness, audit trail integrity verification, backup and restore testing results, change control log review, security incident analysis, and performance against validated parameters. For system retirement, we follow a decommissioning protocol that includes data archival to qualified long-term storage, verification that archived data remains accessible and readable for the full retention period required by applicable predicate rules, formal documentation of the retirement decision and data disposition, and removal of system access. Predicate rules such as 21 CFR 211.180 may require records to be retained for years after the last batch expiration date, so archived data must remain Part 11 compliant throughout.
Ready to Build Part 11 Compliant Software?
Ready to Build Part 11 Compliant Software? image

Ready to Build Part 11 Compliant Software?

From LIMS to electronic batch records to clinical data systems, we build pharmaceutical software with compliance engineered in from the first line of code. Start with a free compliance architecture consultation.

Schedule Free Consultation

© 2026 IntuitionLabs. All rights reserved.

Privacy PolicyTerms of ServiceBook Meeting